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OBJECTIVES: The aim of this study was to investigate serum leptin, adiponectin and paraoxonase1 levels in adult females receiv-
ing pharmacotherapy for various psychiatric disorders.
METHODS: The study group consisted of 32 obese females (mean age 40.53 ± 11.00 years, mean body mass index 35.44 ± 5.33 
kg/m2) who were receiving treatment for psychiatric disorders, and the control group included 22 obese females (mean age 35.95 
± 9.16 years, mean body mass index 30.78 ± 3.33 kg/m2) who were free of psychiatric disorders. Analyses were performed using 
a bioelectrical impedance device. Fasting blood samples were obtained for complete blood count and various biochemical tests, 
including determination of leptin, adiponectin and paraoxonase1 activity.
RESULTS: Body mass index, waist and hip circumference, body fat percentage, fasting blood glucose, insulin, glycosylated he-
moglobin, homeostasis model assesment of insulin resistance, alanine transaminase, aspartate tarnsaminase, and leptin levels were 
significantly higher in the study group than in controls. Although body weight was positively correlated with leptin levels in both 
groups, body weight was negatively correlated with adiponectin levels in the control group and positively correlated with adiponectin 
levels in the study group. In the study group, body mass index and hip circumference correlated positively with leptin levels, hip 
circumference correlated positively with adiponectin levels, and waist to hip ratio correlated positively with paraoxonase levels. In 
the control group, body mass index as well as waist and hip circumferences were positively correlated with leptin levels. Weight, 
body mass index, and hip circumference were also negatively correlated with the adiponectin/leptin ratio in the control group.
CONCLUSION: This study indicates a higher risk for obesity-related disorders, particularly metabolic syndrome, diabetes and 
cardiovascular disease, in patients treated with psychiatric drugs.
KEYWORDS: Adiponectin; Paraoxonase; Psychiatric drugs; Obesity.
INTRODUCTION
Obesity, which is rapidly increasing in prevalence, is 
closely associated with type 2 diabetes, cardiovascular 
diseases and hypertension, as well as metabolic syndrome, 
as well as metabolic syndrome, which is the coexistence 
of all three of these diseases. In addition to energy storage, 
adipose tissue also regulates energy metabolism via secreting 
adipokines into the circulation. Insulin resistance is a primary 
factor in obesity-related disorders.1 By stimulating cellular 
glucose uptake and acting as an antilipolytic hormone, 
652
CLINICS 2008;63(5):651-60Cardiovascular risk in psychiatric disorders
Ozenoglu A et al.
insulin may cause weight gain via direct effects on adipose 
tissue and influencing appetite through hypoglycemia. 
Leptin, which is synthesized by adipocytes, regulates 
appetite and body weight by activating leptin receptors in 
the satiety center of the hypothalamus. Administration of 
leptin reduces nutrient intake and body weight. However, it 
is thought that increased appetite and weight are associated 
with leptin resistance in the hypothalamus in obese people. 
It is also known that insulin stimulates leptin synthesis in 
adipocytes and that, conversely, leptin can both stimulate 
and inhibit insulin secretion by pancreatic beta cells. Plasma 
leptin levels have prominent effects on body mass index 
(BMI) and body fat ratio.
The concentration of adiponectin, a hormone that plays 
a significant role in regulating insulin sensitivity, is reduced 
in obesity and type 2 diabetes.2 Adiponectin is involved 
in lipid and glucose metabolism and insulin resistance.3,4 
Administration of recombinant adiponectin stimulates 
glucose uptake and lipid oxidation in muscles while reducing 
lipid uptake and glucose synthesis in the liver, and increases 
the overall insulin resistance.5 In addition to these effects, 
adiponectin acts as an anti-inflammatory factor and reduces 
the risk of atherosclerosis, hypertension and coronary 
heart disease.6,7 Excess body fat, particularly abdominal 
visceral lipid deposition, is frequently accompanied by 
hypoadiponectinemia, which mediates the relationship 
between obesity and atherosclerotic vascular diseases.8
Hypercholesterolemia, high triglyceride (TG) and low 
density lipoprotein cholesterol (LDL-C) levels and low high 
density lipoprotein cholesterol (HDL-C) levels are frequently 
encountered in obese people. Various studies have shown that 
obese people have increased oxidative stress as well as greater 
sensitivity to lipid peroxidation of LDL when compared to 
healthy controls (9,10). In obesity, LDL oxidation is related 
to disrupted function of HDL in antioxidant defense; this 
disruption is mediated by reduced activity of HDL-associated 
enzymes, such as paraoxanase (HDL-PON1) and lecithin-
cholesterol acyl transferase (11). The risk of diseases related 
to oxidative damage and lipid peroxidation has been suggested 
to be greater in people with low paraoxanase1 (PON1) activity 
than in those with high activity.12
Pharmacotherapy of psychiatric diseases results in 
increased body weight frequently accompanied by increased 
appetite. This side effect, the occurrence and timing of which 
is difficult to estimate, eventually leads to obesity, causing 
cessation of treatment in some patients despite therapeutic 
success. Obesity also increases the risk of development 
of various chronic diseases.13-15 Weight reduction thus 
plays a key role in protection from various diseases as 
well as improved prognoses for diseases that have already 
developed. 
The general clinical approach to psychiatric disorders 
primarily consists of improving the psychiatric situation. 
During treatment, patients frequently gain weight and show 
increased appetite. This increase is generally accepted 
as the result of recovery and not considered important. 
However, after pharmacotherapy induced, increased body 
weight and existing genetic factors could increase the risk of 
chronic diseases. In this study, several biochemical (leptin, 
adiponectin and PON1) and anthropometric factors were 
evaluated with respect to cardiovascular and metabolic 
disease risks in adult women with psychiatric disorders who 
became obese after pharmacotherapy. 
MATERIALS AND METHODS
The study population
The study group included 32 obese adult females (mean 
BMI=35.44 ± 5.33 kg/m2) who were referred to the dietetics 
department due to complaints about increased body weight 
while being treated and followed up for psychiatric disorders 
in the Psychiatry Department of the Cerrahpasa Faculty of 
Medicine in Istanbul University. 
The patients in the study group received pharmacotherapy 
suitable for their psychiatric conditions (i.e., antidepressants, 
antipsychotics, mood stabilizers and anxiolytics). Most patients 
were taking more than one medicine. Their diagnosis had 
already been performed with suitable psychometric evalutions at 
the psychiatry clinic and their treatments have been followed by 
periodic controls. In addition, they had been under psychiatric 
treatment changing from 1 to 20 years, before referral to our 
dietetic department. Patients with depression, anxiety, panic, 
bipolar, obsessive compulsive and psychotic disorders received 
treatment in our outpatient psychiatry clinic. Patients who 
were under pharmacotherapy received different medicines and 
therapies before in long term.
The controls included 22 adult females referred from 
various clinics to the dietetics department for exogenous obesity 
(mean BMI=30.78 ± 3.33 kg/m2); these patients had no known 
endocrine or metabolic disorders or history of drug use. 
Initially, anthropometric measurements, including height 
and weight as well as waist and hip circumference were 
taken. BMI and waist/hip ratios (WHR) were calculated for 
both groups. Body composition analyses were performed 
using a bioelectrical impedance analyzer (BIA) device 
(Bodystat 1500MDD, UK). 
Determination of biochemical parameters
Venous blood samples were drawn into EDTA containing 
dry tubes without venous stasis after 12 hours overnight 
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fasting. Plasma and serum were obtained after at least 30 
minutes of clotting by centrifugation at 2500xg for 15 minutes. 
Serum were removed and used directly for measurements of 
biochemical parameters. Other serum and plasma samples 
were stored at –70 0C until assayed for determination of leptin, 
adiponectin levels and PON1 activity.
Biochemical parameters (serum fasting blood 
glucose, uric acid, ALT (Alanine transaminase), AST 
(Aspartate tarnsaminase), triglyceride, total HDL and 
LDL cholesterol) were measured using an Abbott C8000 
automatic analyzer (Abbott, Japan) for all samples. TSH 
(thyroid stimulating hormone ) , insulin and cortisol were 
measured by chemiluminescent immunometric assay using 
an Immulite 2000 device (DPC; Los Angeles, USA). The 
plasma homocysteine (Hcy) level was determined by high 
performance liquid chromatography (HPLC, Agilent 1100 
Series). Complete blood count (CBC) was measured using 
an HMX analyzer (Beckman Coulter, USA). Serum high 
sensitive C reactive protein (hsCRP) concentrations were 
measured using a Behring BN II nephelometer (Dade 
Behring, Malburg, Germany). Plasma fibrinogen levels were 
measured using a BCT analyzer (Dade Behring, Malburg, 
Germany). Serum B12 and folic acid levels were measured 
by radioimmunoassay (RIA, DPC, USA). Serum ferritins 
were measured using an Abbott IMX device (Abbott Labs, 
Abbott Park, IL, USA). HbA1C levels were measured using 
an HLC-723 G7 HPLC system (Tosoh Corporation, Tokyo, 
Japan). 
Homeostatic model assessment (HOMA) is a method for 
assessing beta- cell function and insulin resistance (HOMA-
IR) from basal (fasting) glucose and insulin. HOMA-IR 
was calculated by the formula [fasting glucose (mmol/L) x 
fasting insulin (µU/ml)] / 22.5. Complete medical history and 
physical examination were performed for each subjects.
Leptin levels in serum samples were assessed via ELISA 
using commercial sandwich ELISA kits (DRG Diagnostic, 
Marburg, Germany). 
Serum PON1 activity was assayed using synthetic 
paraoxon (diethyl-p-nitrophenyl phosphate) as substrate. 
PONl activity was determined by measuring the initial rate 
of substrate hydrolysis to p-nitrophenol, which absorbance 
was monitored at 412 nm in the assay mixture containing 
2.0mM paraoxon, 2, 0 mM CaCl2 and 20 L of plasma in 100 
mM Tris-HCI buffer (pH=8,0). The blank sample containing 
incubation mixture without plasma was run simultaneously 
to correct for spontaneous substrate breakdown. The enzyme 
activity was calculated from E412 of p-nitrophenol (18.290 
per M/cm) and was expressed as U/ml; 1 U of enzyme 
hydrolyses 1 nmol of paraoxon/min (1). Mean intra-assay 
and inter-assay coefficients of variation for this analysis were 
8.7 % and 9.8 %, respectively.
All patient medical and genetic histories, as well as 
biochemical and anthropometric measurements, were 
evaluated by internal medicine specialists. Patients with 
diabetes, dislipidemia, thyroid function disorders or 
inflammatory and autoimmune disorders were not included 
in this study. No special tests were used to evaluate the 
psychiatric conditions of the control group patients. After 
psychiatric evaluation, patients with disorders requiring 
treatment were excluded from the study. The nutritional 
condition of both groups of patients was determined by 
observing food consumption for the past 7 days and through 
in-depth interviews with the patients. Variations in weight 
and appetite of patients during the study were reported from 
both the records of the outpatient clinics and the patients 
themselves.
Following measurement and based on information 
obtained from detailed anamnesis, individualized 
individualized nutritional support was initiated for 
each patient and followed up. However, alterations in the 
biochemical and anthropometric parameters with the impact 
of dietary treatment of patients during the follow up period 
will be described in another study
Statistical analyses were made using Student’s t, Mann-
Whitney U, and Pearson’s correlation tests using SPSS for 
Windows 10.0 software.
RESULTS
The 32 patients in the study group were using psychiatric 
drugs for a mean duration of 5.42 ± 4.91 years. The drugs 
included anxiolytics in 2 (6.3%), antidepressants in 27 
(84.4%), antipsychotics in 10 (31.3%) and mood stabilizers 
in 11 (34.4%) cases. Most patients have been taken more 
than one drug.
Patients in the study had been diagnosed with depression 
(20%), bipolar disorder (5%), schizophrenia (3%), anxiety 
disorders (2%), and obsessive compulsive disorder (1%). 
Anthropometric measurements of all patients that is in the study 
group receiving psychiatric pharmacotherapy and control who 
not receiving any drugs are displayed in Table 1.
For patients in the study group weight, BMI, waist and 
hip circumference and body fat percentage were significantly 
higher than those of the controls, while the lean body mass 
and body water percentage were significantly lower.
Biochemical parameters and leptin, adiponectin and 
PON1 levels for both groups are compared in Table 2. In the 
study group blood glucose, insulin, HbA1c, triglyceride, total 
cholesterol, LDL cholesterol, ferritin, ALT, AST, HOMA-IR 
and leptin levels were significantly higher than those of the 
controls, while the adiponectin levels were significantly 
lower. CRP levels were above reference values (0-5 mg/l) in 
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Table 1 - Anthropometric characteristics of patients receiving and not receiving drugs
Patients not receiving drugs 
Mean ± SD
Patients receiving drugs 
Mean ± SD
P-value
Age (years) 35.95 ± 9.16 40.53 ± 11.00 0.115
Height (cm) 155.91 ± 6.43 156.72 ± 6.84 0.663
Weight (kg) 74.86 ± 9.36 87.25 ± 15.38 0.001
BMI (kg/m2) 30.78 ± 3.33 35.44 ± 5.33 0.001
Waist circumference (cm) 91.19 ± 7.99 101.56 ± 10.34 0.000
Hip circumference (cm) 111.02 ± 8.05 120.37 ± 12.39 0.004
Waist/hip ratio 0.82 ± 0.04 0.85 ± 0.05 0.123
Fat mass (%) 35.99 ± 4.44 42.21 ± 4.77 0.000
Lean mass (%) 64.01 ± 4.44 57.92 ± 5.18 0.000
Body water (%) 46.29± 3.88 42.26 ± 3.84 0.001
BMR(kcal) 1489.90 ± 119.30 1564.27 ± 172.25 0.099
BMI: Body mass index, BMR: Basal metabolic rate
Table 2 - Comparison of biochemical findings between groups
Patients not receiving drugs 
Mean ± SD
Patients receiving drugs 
Mean ± SD
P-value
Glucose (mg/dl) 86.36 ± 10.59 95.16 ± 11.64 0.007
Insulin (micU/ml) 10.52 ± 3.68 15.51 ± 7.52 0.006
HbA1c (%) 5.63 ± 0.39 5.94 ± 0.51 0.020
Triglycerides (mg/dl) 111.86 ± 62.45 139.94 ± 59.22 0.029
Total cholesterol (mg/dl) 182.86 ± 43.73 203.28 ± 39.17 0.017
HDL (mg/dl) 43.27 ± 9.35 47.56 ± 10.68 0.133
LDL (mg/dl) 114.35 ± 30.47 130.44 ± 27.73 0.049
Hemoglobin (g/dl) 12.84 ± 0.81 12.86 ± 0.84 0.919
Hematocrit (%) 38.06 ± 2.24 37.79 ± 2.42 0.679
Ferritin (ng/ml) 21.29 ± 14.00 33.70 ± 23.89 0.043
Vitamin B12 (pg/ml) 298.55 ± 158.32 282.91 ± 171.85 0.744
Folate (ng/ml) 4.65 ± 2.21 5.49 ± 2.67 0.242
ALT (U/l) 17.17 ± 5.60 26.17 ± 14.51 0.016
AST (U/l) 17.50 ± 4.00 21.21 ± 6.99 0.047
CRP (mg/l) 4.27 ± 2.99 7.63 ± 7.11 0.057
Uric acid (mg/dl) 4.66 ± 0.89 4.31 ± 1.00 0.227
Fibrinogen (mg/dl) 550.63 ± 175.33 469.53 ± 137.11 0.079
Cortisol (µg/dl) 9.76 ± 4.31 13.21 ± 9.20 0.131
Homocysteine (µmol/l) 10.42 ± 3.31 10.78 ± 5.85 0.806
TSH (mIU/ml) 1.91 ± 0.86 2.28 ± 3.10 0.588
HOMA-IR 2.26 ± 0.88 3.75 ± 2.12 0.003
Leptin (ng/ml) 74.49 ± 25.10 87.75 ± 18.03 0.028
Adiponectin (ng/ml) 8.22 ± 5.07 6.24 ± 3.73 0.037
PON1 (U/ml) 258.29 ± 101.95 232.48 ± 80.98 0.305
Adiponectin/leptin ratio 0.15 ± 0.16 0.08 ± 0.07 0.073
PON1/HDL ratio 6.15 ± 2.45 5.14 ± 2.39 0.137
HbA1c: glycosilated hemoglobin, TSH: tyroid stimulan hormone, PON1: paraoxanase1, HOMA-IR: homeostasis model assesment of insulin resistance, 
ALT: Alanine transaminase, AST: Aspartate tarnsaminase
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the study group, while the fibrinogen levels were above the 
reference range (180-350 mg/dl) in both groups.
Differences in several parameters were re-evaluated 
following adjustment for age and BMI. When age was 
adjusted to 38.67 years and BMI was adjusted to 33.54 kg/
m2, the mean adiponectin level was 5.838 ± 0.709 ng/ml for 
patients receiving drugs and 8.804 ± 0.709 ng/ml for controls 
(p=0.017).
In the controls, leptin levels correlated positively with 
weight (r=0.64; p=0.001), BMI (r=0.604; p=0.003), waist 
circumference (r=0.501; p=0.021), hip circumference 
(r=0.701; p=0.000), and Hcy (r=0.449; p=0.036) and 
negatively with the adiponectin/leptin ratio (r=-0.734; 
p=0.000).
Also in the controls, adiponectin levels were positively 
correlated with the PON1 level (r=0.433; p=0.044), 
adiponectin/leptin ratio (r=0.0753; p=0.000), and vitamin 
B12 level (r=0.652; p=0.002).
PON1 was only positively correlated with the PON1/
HDL ratio (r=0.828; p=0.000).The adiponectin/leptin ratio 
was negatively correlated with weight (r=-0.524; p=0.012), 
BMI (r=-0.456; p=0.033), hip circumference (r=-0.534; 
p=0.013), and Hcy level (r=-0.503; p=0.017) and positively 
correlated with the vitamin B12 level (r=0.471; p=0.036).
Among the study group, leptin levels were positively 
correlations with weight (r=0.446; p=0.01), BMI (r=0.396; 
p=0.025), and hip circumference (r=0.389; p=0.031) and 
negatively correlated with the adiponectin/leptin ratio 
(r=-0.654; p=0.000). Adiponectin levels were positively 
correlated with the adiponectin/leptin ratio (r=0.768; 
p=0.000) as well as glucose (r=0.365; p=0.04), HDL 
(r=0.371; p=0.037), and folate levels (r=0.430; p=0.014) and 
was negatively correlated with fibrinogen levels (r=-0.464; 
p=0.015).PON1 was positively correlated with the PON1/
HDL ratio and WHR (r=0.743; p=0.000). The PON1/HDL 
ratio was positively correlated with the triglyceride level 
(r=0.377; p=0.033) and negatively correlated with the HDL 
level (r=-0.488; p=0.005).
DISCUSSION
During treatment of various diseases, increased body 
weight is regarded as a sign of improvement. However, drug-
induced alterations of the mechanisms regulating appetite 
may result in excessive weight gain and thus endanger 
compliance with the medical treatment. Various drugs can 
alter body weight as a negative outcome of their therapeutic 
effects.16 These drugs include psychotropic drugs such 
as antipsychotics, antidepressants and mood stabilizers. 
Weight gain is thought to be partially caused by both reduced 
physical activity caused by the sedative effects of the drugs 
and excessive consumption of high-calorie drinks.
Excessive fat deposition in adipose tissue and abdominal 
distribution of this fat negatively influence health in humans. 
Abdominal obesity is strongly related to disorders involving 
glucose, insulin and lipid metabolism.17-20 In addition to its 
role in energy storage, adipose tissue also secretes various 
biologically active adipokines. Among these, leptin and 
adiponectin have significant roles in insulin sensitivity.
Insulin and leptin play roles in the regulation of body 
weight. In one study,21 the levels of these hormones were 
investigated in patients treated with various antipsychotics, 
and patients receiving olanzapine had higher insulin levels 
than those treated with conventional antipsychotics despite 
similar BMI values. This situation was attributed to possible 
effects of olanzapine on insulin secretion. Leptin regulation 
also changes during olanzapine and clozapine therapy, and 
the effects of these drugs on insulin and leptin levels were 
proposed to be associated with the induction of weight 
gain.
In our study, patients treated with various psychotropic 
drugs had significantly higher glucose, insulin, HOMA-IR, 
leptin, triglyceride, total cholesterol and LDL cholesterol 
levels than the controls despite belonging to the same 
BMI group (BMI>30.00 kg/m2). Body fat mass (%) as 
well as waist and hip circumference measurements were 
also significantly higher in patients receiving drugs. The 
significantly higher hepatic enzyme levels in the study group 
may have been due not only to disorders caused by obesity 
but also to drug therapy. This indicates that psychotropic 
drugs may increase the risk of developing of metabolic and 
cardiovascular disorders by affecting hormones related to 
body weight.
Weight gain caused by psychotropic drug treatment 
has been proposed to be associated with increased leptin 
levels. During acute treatment of schizophrenia with 
clozapine, serum leptin increased two-fold within 2 weeks 
of initiating therapy and remained high for the first 10 
weeks of treatment. Body weight increased by a mean of 
4.2 kg within this period.22 Patients treated with clozapine or 
olanzapine for 4 weeks had mean weight gains of 2.3 and 3.9 
kg, respectively; this was compatible with increased leptin 
secretion. On the other hand, patients who were treated with 
haloperidol or did not receive psychotropic drugs gained no 
weight and had stable leptin levels.23
Metabolic syndrome is common among patients treated 
for schizophrenia,24 indicating a significant increase in 
the risk of cardiovascular and metabolic disorders. It has 
therefore been stressed that an initial evaluation and follow-
up to assess metabolic syndrome-related risks should be a 
part of the clinical treatment for schizophrenic patients.
In a longitudinal study,25 a mean body weight increase of 
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3.3 kg was associated with a significant increase in plasma 
leptin levels following the 8th week of acute olanzapine 
therapy. Within the first 8 weeks of lithium monotherapy, 
body weights of eight female and seven male inpatients 
increased by a mean of 5.9 kg, whereas leptin levels 
increased significantly from a basal value of 6.9 ng/ml to 
10.3 ng/ml.26
During 6 weeks of treatment with tricyclic antidepressants 
and paroxetine, body weight increased by 3.5 and 1.0 kg, 
respectively, whereas no change was observed in depressed 
patients who did not receive pharmacotherapy. On the other 
hand, plasma leptin levels did not change in any of the 
groups.27
In a comparative study in which the effects of atypical 
antipsychotics, including quetiapine, olanzapine, risperidone 
and clozapine, on leptin and triglyceride levels and body 
weight were investigated,28 olanzapine and clozapine caused 
significant increases in leptin and triglyceride levels, as well 
as in body weight. The increases in these parameters were 
moderate with quetiapine and minimal with risperidone. 
Also, leptin levels correlated positively with BMI and 
triglyceride levels.
In our study group, most patients were depressed and 
receiving antidepressant pharmacotherapy (62.5%). The 
period of treatment and the initial body weights may affect 
the results of the study. In our study, the leptin level in both 
groups was positively correlated with body weight, BMI and 
waist and hip measurements. This result is compatible with 
previous studies and was expected.
The blood concentrations of adiponectin, which increases 
insulin sensitivity, are reduced in obesity and type 2 
diabetes.2 In our study, adiponectin levels were significantly 
lower in the pharmacotherapy group (p=0.037, Table 2). In 
humans, adiponectin levels are known to correlate negatively 
with body weight, body fat mass and insulin levels.
In addition to its association with lipid and glucose 
metabolism and insulin resistance, adiponectin also acts 
as an anti-inflammatory agent3,29,30 and might contribute 
to the development of obesity-related disorders such 
as atherosclerosis, hypertension and coronary heart 
disease.6,30,31 Excess body fat deposition, particularly that 
of abdominal visceral fat, is frequently associated with 
hypoadiponectinemia, a known mediator of the association 
between obesity and atherosclerotic vascular disorders.8
In our study, the mean adiponectin levels of the group 
using psychotropic drugs were significantly lower than those 
of the controls (Table 2). Although all the patients in the 
study were obese (BMI >30 kg/m2), there was a significant 
difference between the BMI values of the two groups. 
Therefore, several parameters were re-evaluated following 
adjustment of age and BMI. Following adjustment to an age 
of 38.67 years and a BMI of 33.54 kg/m2, mean adiponectin 
levels were 5.838 ± 0.709 ng/ml in the group receiving drugs 
and 8.804 ± 0.877 ng/ml in the control group; this difference 
was statistically significant (p=0.017).
Plasma adiponectin and leptin levels, body composition, 
and glucose consumption were previously investigated in 
adult females with different ages and obesity levels.32 In that 
study, plasma adiponectin levels did not vary with age but 
were negatively associated with body fat percentage, visceral 
fat, subcutaneous abdominal fat, and insulin and leptin 
levels. Adiponectin levels were also positively correlated 
with glucose consumption.
In our study, adiponectin levels were positively correlated 
with age in patients receiving psychiatric drugs (r=0.525; 
p=0.002). In patients receiving drugs, adiponectin was 
positively correlated with glucose, HDL and folate levels 
as well as the adiponectin/leptin ratio and was negatively 
correlated with fibrinogen levels. Adiponectin was positively 
correlated with PON1 and vitamin B12 levels as well as 
the adiponectin/leptin ratio in the control group. These 
results further suggest the association of adiponectin with 
cardiovascular diseases.
Hypoadiponectinemia has been reported to be more 
strongly correlated than other inflammatory indicators 
with diabetes and metabolic syndrome.33 Reduced plasma 
adiponectin levels are also encountered in conditions that 
are frequently associated with insulin resistance, such as 
cardiovascular diseases and hypertension.34,35
Both stress and drugs affect the appetite and dietary 
choices of our patients, who tend to show particularly 
increased affinity for fatty and sweet foods. The 
neuroendocrine system is activated by stress, resulting in 
increased secretion of epinephrine, norepinephrine, cortisol, 
growth hormone and glucagon.36 These neuroendocrine 
alterations lead to hyperglycemia by affecting the regulation 
of plasma glucose. In our study, the cortisol levels appeared 
higher in the group receiving psychiatric drugs, although 
this difference was not statistically significant (Table 2). 
Stress-induced activation of the neuroendocrine system and 
the resulting effects on carbohydrate metabolism may have 
been responsible for the significantly higher glucose, insulin, 
HbA1c and HOMA-IR levels in patients who were receiving 
drugs. The duration of drug therapy was also positively 
correlated with HbA1c levels in the group receiving drugs 
(r=0.371, p=0.040). These results suggest that psychiatric 
disorders and their corresponding treatments render patients 
more susceptible to type 2 diabetes mellitus, metabolic 
syndrome and cardiovascular diseases.
Obesity is an independent risk factor for coronary artery 
disease and also indirectly increases the risk of coronary 
artery disease via its associations with insulin resistance, 
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hyperlipidemia and hypertension37. Visceral adiposity, 
which describes fat deposition within the abdomen, is 
highly correlated with an unfavorable coronary risk profile. 
Therefore, measurements of waist circumference and body 
fat have become increasingly popular in clinics. A waist 
circumference of greater than 80 cm in females indicates 
increased risk of metabolic syndrome and cardiovascular 
diseases.38 In our study, the waist circumference was greater 
than this limit in both groups and was also significantly 
higher in the group receiving psychiatric drugs than in the 
control group. Hip circumference and body fat percentage 
were also significance higher in the group receiving drugs 
(Table 1). While the body fat ratio of controls was in accord 
with the level expected according to BMI,39 it was above the 
expected value in the group receiving psychiatric drugs.
The presence of metabolic syndrome in patients with 
type 2 diabetes mellitus indicates a particularly high risk 
for cardiovascular diseases.40 In patients with metabolic 
syndrome, levels of prothrombotic factors, such as fibrinogen 
and PAI-1, are usually high. Levels of acute phase reactants 
such as CRP and fibrinogen as well as those of cytokines 
(e.g., TNF-alpha and IL-6) are also increased. CRP levels 
tend to be higher in patients with metabolic syndrome than 
in healthy individuals.40 A high CRP level (>3 mg/l) is 
considered an overt risk factor for cardiovascular diseases.41 
In our study, both CRP and fibrinogen levels were high 
in both groups, while CRP levels were greater than the 
reference range of our laboratory (0-5 mg/l) in the group 
receiving drugs (Table 2). In the group receiving psychiatric 
drugs, adiponectin levels were positively correlated with 
HDL (r=0.371, p=0.037) and folate (r=0.430, p=0.014) levels 
and negatively correlated with fibrinogen levels (r=-0.464, 
p=0.015); no such correlation of adiponectin with fibrinogen 
was observed in the controls (r=-0.100, p=0.667). Levels of 
ferritin, an acute phase reactant, were significantly higher in 
the patients receiving drugs (Table 2). The parallel increases 
in levels of inflammatory markers and waist circumference 
and body fat content in addition to the other biochemical 
findings support the hypothesis that patients receiving 
psychiatric drugs are at greater risk for metabolic syndrome 
and cardiovascular diseases than obese individuals who do 
not receive psychiatric pharmacotherapy.
In the Amamoto T at all ‘s study, the effects of the 
antipsychotic chlorpromazine on body weight, glucose 
and lipid metabolism, and adipocytokine secretion were 
investigated in rats fed with sucrose,42 adiponectin levels 
were significantly higher in the group receiving sucrose than 
in the controls, whereas they were not altered in the group 
receiving both sucrose and chlorpromazine. On the other 
hand, plasma TNF-alpha levels were significantly greater in 
the group receiving both sucrose and chlorpormazine than in 
the group receiving sucrose only. Both of these groups had 
significantly higher fasting glucose and insulin levels than 
the control group. These results were attributed to inhibition 
of the adiponectin by chlorpromazine to compensate for 
increased plasma TNF-alpha levels; this is compatible with 
obesity.
PON is an enzyme particularly associated with HDL 
levels that has a significant functional role in the prevention 
of lipid peroxidation, which increases the tendency of 
developing atherogenesis and dementia.43,44 45
Altered lipid and lipoprotein metabolism in obese 
individuals have been demonstrated in several studies. 
Hypercholesterolemia, high triglyceride and LDL levels, 
and low HDL levels are frequently encountered in obese 
people. The altered lipoprotein levels and composition are 
possibly associated with a higher obesity-related risk of 
cardiovascular diseases. Increased oxidative stress paralleling 
increased sensitivity of LDL to lipid peroxidation has also 
been shown in obese individuals.9,10 Increased oxidative 
damage has been probably related to reduced antioxidant 
capacity. In animal studies, LDL oxidation in obesity was 
associated with disruption of antioxidant defense by HDL, 
including reduced activities of HDL-associated enzymes 
such as paraoxanase (HDL-PON) and lecithin cholesterol 
acyltransferase.11
HDL-PON is a calcium-dependent esterase that can 
hydrolyze oxidized phospholipids, thereby protecting 
lipoproteins (LDL, HDL) and membranes from oxidative 
changes.12 The enzymatic activity of PON-HDL varies 
greatly among healthy people, and individuals with low PON 
activity are at greater risk for developing diseases involving 
oxidative stress and lipid peroxidation.12 Previous studies 
have also shown that the antioxidant capacity of HDL and 
its sensitivity to atherogenic modifications such as oxidation, 
glycation and homocysteinization are associated with HDL-
PON activity.46,47
In a study that investigated the relationship between 
HDL-PON activity and oxidative stress of lipoproteins 
in healthy and obese individuals43, HDL-PON activity 
was significantly lower in obese people than in controls. 
The negative correlation between HDL-PON activity and 
lipid peroxide levels suggested an association between 
paraoxonase activity and lipid peroxidation of lipoproteins. 
The finding that plasma leptin levels correlated negatively 
with HDL-PON activity and positively with lipid hydroxy 
peroxide levels in obese individuals was attributed to 
the relationship between leptin and oxidative damage of 
lipoproteins. The authors thus concluded that reduced 
paraoxonase activity and compositional alterations of HDL 
and LDL contribute to increased risk of obesity-related 
cardiovascular diseases.
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The PON/HDL ratio positively correlated with the 
HOMA index, BMI and WHR48. The authors thus concluded 
that in a population without hyperglycemia, insulin 
resistance and hyperinsulinemia are factors contributing to 
the variability in the intragenotype of paraoxanase activity.
Although the PON1 levels and PON1/HDL ratios 
appeared in our study in patients receiving drugs lower 
than controls, the difference was not statistically significant 
(Table 2). In the patients receiving drugs, PON1 was 
positively correlated with BMI, while the PON1/HDL 
ratio was positively correlated with triglyceride levels and 
negatively correlated with HDL levels. No such association 
was observed in controls. The results in patients receiving 
drugs are compatible with other findings indicating increased 
cardiovascular disease risk.
While previous studies have investigated leptin and 
adiponectin levels in patients receiving pharmacotherapy 
for psychiatric disorders, our study is the first in which 
HDL-PON1 activity was also assessed in addition to a wide 
spectrum of biochemical parameters.
The epidemiology of obesity plays a significant role 
in the high prevalence of metabolic syndrome. Abdominal 
obesity is strongly related to disorders involving glucose, 
insulin and lipid metabolism.17-20,49 Increased nutrient intake, 
together with inactivity, contributes to increased deposition 
visceral fat tissue and eventually leads to insulin resistance. 
The visceral fat mass correlates positively with the severity 
of insulin resistance.50
Depending on the dietary history and food records of 
patients in study group, it was revealed that while total 
caloric intake, saturated fat and refined carbohydrate 
content in their diet were increasing complex carbohydrate, 
antioxidant vitamins, essential fat and fiber rich foods 
consumption decreased. 
In addition to underlying diseases and pharmacotherapy, 
lack of essential ingredients in the diet may increase 
susceptibility to certain chronic diseases. The patients who 
require pharmacotherapy for psychiatric disorders should 
be treated and followed up with a multidisciplinary team 
approach. The presence of a dietician in the treatment team 
with experience in the areas of endocrinology, metabolism 
and psychiatry who is also talent in communication skills 
with patients could be important for treatment success At 
psychiatric clinics, the development of hormonal disorders 
and metabolic nutritional alterations are sometimes neglected 
or not considered important. However, this approach may 
contribute to the development of other chronic diseases. We 
therefore believe and recommend that inclusion of a qualified 
and skilled dietitian could be beneficial when creating the 
treatment team. 
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